Current Report Filing (8-k)
January 10 2023 - 8:01AM
Edgar (US Regulatory)
0001788028
false
0001788028
2023-01-10
2023-01-10
0001788028
JSPR:VotingCommonStockParValue0.0001PerShareMember
2023-01-10
2023-01-10
0001788028
JSPR:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member
2023-01-10
2023-01-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): January 10, 2023
JASPER
THERAPEUTICS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware |
|
001-39138 |
|
84-2984849 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
2200
Bridge Pkwy Suite #102
Redwood City, California 94065
(Address
of Principal Executive Offices) (Zip Code)
(650)
549-1400
Registrant’s
telephone number, including area code
N/A
(Former
Name, or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Exchange Act:
(Title
of each class) |
|
(Trading
Symbol) |
|
(Name
of exchange on which registered) |
Voting
Common Stock, par value $0.0001 per share |
|
JSPR |
|
The
Nasdaq Stock Market LLC |
Redeemable
Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50 |
|
JSPRW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
7.01. Regulation FD Disclosure.
On
January 10, 2023, Jasper Therapeutics, Inc. (the “Company”) issued a press release announcing that, as part of an overall
portfolio prioritization, the Company will focus primarily on the development of its lead product candidate, briquilimab (formerly known
as JSP191), in chronic diseases and stem cell transplant for rare diseases. A copy of the press release is furnished herewith as Exhibit
99.1 to this Current Report on Form 8-K.
The
Company is also furnishing an updated corporate presentation, attached as Exhibit 99.2 to this Current Report on Form 8-K (the “Corporate
Presentation”), which the Company intends to post on the Company’s website. The Corporate Presentation is current as
of January 10, 2023, and the Company disclaims any obligation to update this material in the future.
The
information in this Item 7.01, including the press release attached hereto as Exhibit 99.1 and the Corporate Presentation attached hereto
as Exhibit 99.2, is being furnished under Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth by specific reference in such a filing.
Item
9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: January 10, 2023 |
JASPER THERAPEUTICS, INC. |
|
|
|
|
By: |
/s/ Jeet Mahal |
|
|
Name: |
Jeet Mahal |
|
|
Title: |
Chief Operating Officer and
Chief Financial Officer |
2
Amplitude Healthcare Acq... (NASDAQ:AMHCU)
Historical Stock Chart
From Jul 2024 to Aug 2024
Amplitude Healthcare Acq... (NASDAQ:AMHCU)
Historical Stock Chart
From Aug 2023 to Aug 2024